Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16942065 | 0.92 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL25391589 | 0.92 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL30748702 | 0.92 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL25390706 | 0.92 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL12806526 | 0.87 | KMT2A (0.55) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL30277387 | 0.87 | KMT2A (0.55) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL3087950 | 0.85 | KMT2A (0.58) | KMT2AEPHX2CASP3 | |
| SCHEMBL16769614 | 0.84 | KMT2A (0.56) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL2744429 | 0.83 | KMT2A (0.51) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL8263309 | 0.83 | KMT2A (0.51) | KMT2AEPHX2LMNASMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200254110-A1 | LIGAND-CONJUGATES AND METHODS FOR TARGETED RECEPTOR-MEDIATED CELLULAR UPTAKE | UNIVERSITY OF BREMEN (DE) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200254110-A1 | LIGAND-CONJUGATES AND METHODS FOR TARGETED RECEPTOR-MEDIATED CELLULAR UPTAKE | ASGR1, HAVCR2, LDLR | KMT2A 4235/4885EPHX2 2104/4885LMNA 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.